The purpose was to determine the relationship between the expression of bone marrow BCMA and the classification, stage, and prognostic factors of MM, so as to identify the main factors that should be considered in the selection process of suitable MM patients for BCMA CAR-T therapy, and to provide guidance for the clinical application of this immunotherapy. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.